For research use only. Not for therapeutic Use.
Tirasemtiv (Cat.No:I000090) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.
| Catalog Number | I000090 |
| CAS Number | 1005491-05-3 |
| Molecular Formula | C12H14N4O |
| Purity | ≥95% |
| Target | Alkynes |
| Solubility | DMSO: ≥ 52 mg/mL |
| Storage | Store at -20°C |
| Reference | </br>1:A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, Andrews JA; ; ON BEHALF OF THE BENEFIT-ALS STUDY GROUP..Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):426-35. doi: 10.3109/21678421.2016.1148169. Epub 2016 Mar 16. PMID: 26982815 </br>2:A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI; Tirasemtiv in Myasthenia Gravis Study Group..Neurotherapeutics. 2015 Apr;12(2):455-60. doi: 10.1007/s13311-015-0345-y. PMID: 25742919 Free PMC Article</br>3:Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR.Vasc Med. 2014 Aug;19(4):297-306. Epub 2014 May 28. PMID: 24872402 </br>4:Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR.PLoS One. 2014 May 7;9(5):e96921. doi: 10.1371/journal.pone.0096921. eCollection 2014. PMID: 24805850 Free PMC Article</br>5:Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI.Muscle Nerve. 2014 Dec;50(6):925-31. doi: 10.1002/mus.24239. PMID: 24634285 Free PMC Article</br>6:A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Shefner JM, Watson ML, Meng L, Wolff AA; Neals/Cytokinetics STUDY Team..Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81. doi: 10.3109/21678421.2013.822517. Epub 2013 Aug 19. PMID: 23952636 </br>7:The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Shefner JM, Wolff AA, Meng L.Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):582-5. doi: 10.3109/21678421.2013.817587. Epub 2013 Aug 19. PMID: 23952600 |
